Upon treatment of the nanocarrier system to tumors, surface-anchored Paclitaxel would be released initially upon reaching the tumor site, exerting cytotoxic effects on tumor cells, and stopping tumor cell-initiated Redd1 upregulation. This evidence concerns the gene DDIT4 and neoplasm.